Revenue Breakdown
Composition ()
No data
Revenue Streams
Edwards Lifesciences Corp (EW) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Transcatheter Aortic Valve Replacement, accounting for 73.8% of total sales, equivalent to $1.13B. Other significant revenue streams include Surgical Heart Valve Therapy and Transcatheter Mitral and Tricuspid Therapies. Understanding this composition is critical for investors evaluating how EW navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Edwards Lifesciences Corp maintains a gross margin of 77.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.37%, while the net margin is 18.82%. These profitability ratios, combined with a Return on Equity (ROE) of 13.59%, provide a clear picture of how effectively EW converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, EW competes directly with industry leaders such as IDXX and BDX. With a market capitalization of $47.83B, it holds a significant position in the sector. When comparing efficiency, EW's gross margin of 77.77% stands against IDXX's 61.83% and BDX's 47.51%. Such benchmarking helps identify whether Edwards Lifesciences Corp is trading at a premium or discount relative to its financial performance.
